Cell line development for the generation of Medannex’s anti-Annexin A1 antibodies is under way, at FUJIFILM Diosynth Biotechnologies’ (Fujifilm) Billingham, UK site.
Medannex’s novel antibodies are being developed as potentially ground-breaking therapies for cancers and autoimmune diseases. The cell line development, via Fujifilm’s ApolloX advanced expression technology, is part-funded by Scottish Enterprise’s SMART: SCOTLAND R&D awards scheme.
The initiation of this production process follows a recent Series B investment of £11 million for Medannex to accelerate its therapeutic antibody development programme towards clinical trials.
Dr Fiona Dempsey, Director of Scientific Operations at Medannex, said: “We’re delighted to be taking this significant step on our journey towards the clinic, and to be moving closer to our goal of providing new treatments to help patients and their families.”